A Multicenter, Randomized Controlled Study of the Efficacy of Once-Weekly DPP-4 Inhibitor Omarigliptin in Patients with Type 2 Diabetes Undergoing Maintenance Hemodialysis

被引：0
|
作者：
Yoshizawa, Yuta
Hosojima, Michihiro
Kabasawa, Hideyuki
Tanabe, Naohito
Kitamura, Tadahiro
Narita, Ichiei
Saito, Akihiko
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-29-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
29-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [31] PHARMACOKINETICS OF OMARIGLIPTIN (MK-3102), A ONCE-WEEKLY DIPEPTIDYL PEPTIDASE-IV (DPP-4) INHIBITOR, IN PATIENTS WITH RENAL IMPAIRMENT
    Tatosian, D. A.
    Glasgow, S.
    Caceres, M.
    Grenier, J.
    DeGroot, B.
    Ward, T.
    Johnson-Levonas, A.
    George, L.
    Lasseter, K. C.
    Marbury, T. C.
    Kauh, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S90 - S90
  • [32] Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes
    Hideo Otsuki
    Takeo Kosaka
    Kenzo Nakamura
    Fumihiko Shimomura
    Yoshitaka Kuwahara
    Takuji Tsukamoto
    International Urology and Nephrology, 2014, 46 : 427 - 432
  • [33] Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes
    Otsuki, Hideo
    Kosaka, Takeo
    Nakamura, Kenzo
    Shimomura, Fumihiko
    Kuwahara, Yoshitaka
    Tsukamoto, Takuji
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 (02) : 427 - 432
  • [34] Effect of MK-3102, a novel once-weekly DPP-4 inhibitor, over 12 weeks in patients with type 2 diabetes mellitus
    Gantz, I.
    Chen, M.
    Mirza, A.
    Suryawanshi, S.
    Davies, M. J.
    Goldstein, B. J.
    DIABETOLOGIA, 2012, 55 : S51 - S51
  • [35] Glycemic control of once-weekly and other administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes: a real-world retrospective cohort study
    Koto, Ruriko
    Yoshida, Shiori
    Nakajima, Akihiro
    Miwa, Tetsuya
    Nishimura, Rimei
    DIABETOLOGY INTERNATIONAL, 2024, 15 (03) : 632 - 637
  • [36] Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects
    Krishna, Rajesh
    Addy, Carol
    Tatosian, Daniel
    Glasgow, Xiaoli S.
    Gendrano, Isaias Noel, III
    Robberechts, Martine
    Haazen, Wouter
    de Hoon, J. N.
    Depre, Marleen
    Martucci, Ashley
    Peng, Joanna Z.
    Johnson-Levonas, Amy O.
    Wagner, John A.
    Stoch, S. Aubrey
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (12): : 1528 - 1537
  • [37] EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR IN HEMODIALYSIS PATIENTS WITH TYPE 2 DIABETES
    Abe, Masanori
    Okada, Kazuyoshi
    Oikawa, Osamu
    Maruyama, Noriaki
    Furukawa, Tetsuya
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 216 - 216
  • [38] A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes
    Home, Philip
    Shankar, R. Ravi
    Gantz, Ira
    Iredale, Carol
    O'Neill, Edward A.
    Jain, Lokesh
    Pong, Annpey
    Suryawanshi, Shailaja
    Engel, Samuel S.
    Kaufman, Keith D.
    Lai, Eseng
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 138 : 253 - 261
  • [39] Effects of Age, Gender and Obesity on the Single Dose Pharmacokinetics (PK) of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
    Addy, Carol
    Tatosian, Daniel
    Hou, Xiaoli S.
    Gendrano, Isaias N.
    Martucci, Ashley
    Wagner, John A.
    Stoch, S. Aubrey
    DIABETES, 2013, 62 : A301 - A301
  • [40] Efficacy and safety of trelagliptin, a novel once-weekly oral DPP-4 inhibitor: a phase 3, double-blind, non-inferiority study in Japanese type 2 diabetes mellitus patients
    Inagaki, N.
    Onouchi, H.
    Sano, H.
    Kuroda, S.
    Kaku, K.
    DIABETOLOGIA, 2014, 57 : S328 - S328
12345